Aclaris Therapeutics, Inc. (ACRS): Entry into a Material Definitive Agreement
Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 acrs-20260806xex10d1.htm EX-10.1 Exhibit 10.1 ACLARIS THERAPEUTICS, INC. Shares of Common Stock ($0.00001 par value per share) SECOND AMENDED AND RESTATED SALES AGREEMENT August 6, 2026 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York
How this was made
The 30-second read
Why it matters
An ATM program allows the company to sell shares from time to time, typically at market prices, which can create an overhang if investors expect dilution. However, the excerpt provides agreement mechanics rather than a stated near-term issuance amount.
Market read
This is a financing-structure disclosure that can influence dilution expectations and trading around future prospectus supplements or issuance notices.
What to watch
The excerpt does not specify the maximum program amount or any actual sales schedule, so the market impact may be muted until an Issuance Notice or prospectus supplement details timing and size.
Background
The 8-K Item 1.01 reports entry into a material definitive agreement, here an amended and restated ATM sales agreement with sales agents.
Ticker impact
Aclaris Therapeutics entered a Second Amended and Restated Sales Agreement for an at-the-market (ATM) common stock offering via agents.
Near-term pressure is possible if traders interpret the ATM as incremental dilution, but direction depends on whether proceeds fund catalysts not disclosed here.
The 8-K is a primary disclosure of an amended ATM sales agreement, including a 3% selling commission and sales mechanics, but it does not state a specific dollar amount to be raised or any new clinical/financial guidance in the provided excerpt.
Market effects
Biopharma names with ATM programs can see similar dilution-risk sensitivity, especially around financing-related filings.
Primarily US small/mid-cap biotech sentiment, limited spillover expected.
Low global relevance; this is company-specific financing mechanics.
Counterpoint
Traders may view the amended ATM as routine housekeeping to preserve financing flexibility, not an immediate large overhang.
Key entities
- issuerAclaris Therapeutics, Inc.
Subject of the 8-K and party to the amended ATM sales agreement.
- sales_agentLeerink Partners LLC
One of the agents/principals under the sales agreement.
- sales_agentCantor Fitzgerald & Co.
One of the agents/principals under the sales agreement.
- regulatorSEC
Referenced via registration statement and prospectus requirements under the Securities Act/Exchange Act.
